These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 33480665)

  • 41. Exclusive oral antibiotic treatment for hospitalized community-acquired pneumonia: a post-hoc analysis of a randomized clinical trial.
    Dinh A; Duran C; Ropers J; Bouchand F; Deconinck L; Matt M; Senard O; Lagrange A; Mellon G; Calin R; Makhloufi S; de Lastours V; Mathieu E; Kahn JE; Rouveix E; Grenet J; Dumoulin J; Chinet T; Pépin M; Delcey V; Diamantis S; Benhamou D; Vitrat V; Dombret MC; Renaud B; Claessens YE; Labarère J; Bedos JP; Aegerter P; Crémieux AC;
    Clin Microbiol Infect; 2024 Aug; 30(8):1020-1028. PubMed ID: 38734138
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial.
    Kollef MH; Nováček M; Kivistik Ü; Réa-Neto Á; Shime N; Martin-Loeches I; Timsit JF; Wunderink RG; Bruno CJ; Huntington JA; Lin G; Yu B; Butterton JR; Rhee EG
    Lancet Infect Dis; 2019 Dec; 19(12):1299-1311. PubMed ID: 31563344
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparative efficacies and tolerabilities of intravenous azithromycin plus ceftriaxone and intravenous levofloxacin with step-down oral therapy for hospitalized patients with moderate to severe community-acquired pneumonia.
    Zervos M; Mandell LA; Vrooman PS; Andrews CP; McIvor A; Abdulla RH; de Caprariis PJ; Knirsch CA; Amsden GW; Niederman MS; Lode H
    Treat Respir Med; 2004; 3(5):329-36. PubMed ID: 15606222
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and tolerability of piperacillin/tazobactam versus ceftazidime in association with amikacin for treating nosocomial pneumonia in intensive care patients: a prospective randomized multicenter trial.
    Alvarez-Lerma F; Insausti-Ordeñana J; Jordá-Marcos R; Maraví-Poma E; Torres-Martí A; Nava J; Martínez-Pellús A; Palomar M; Barcenilla F;
    Intensive Care Med; 2001 Mar; 27(3):493-502. PubMed ID: 11355117
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Randomized, open-label, parallel-group, multicenter study of the efficacy and tolerability of IV gatifloxacin with the option for oral stepdown gatifloxacin versus IV ceftriaxone (with or without erythromycin or clarithromycin) with the option for oral stepdown clarithromycin for treatment of patients with mild to moderate community-acquired pneumonia requiring hospitalization.
    Corrêa JC; Badaró R; Bumroongkit C; Mera JR; Dolmann AL; Juárez Martínez LG; Mayrinck LR; Tamez R; Yang JY
    Clin Ther; 2003 May; 25(5):1453-68. PubMed ID: 12867221
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cost-effectiveness of gatifloxacin vs ceftriaxone with a macrolide for the treatment of community-acquired pneumonia.
    Dresser LD; Niederman MS; Paladino JA
    Chest; 2001 May; 119(5):1439-48. PubMed ID: 11348951
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ceftaroline fosamil versus ceftriaxone for the treatment of Asian patients with community-acquired pneumonia: a randomised, controlled, double-blind, phase 3, non-inferiority with nested superiority trial.
    Zhong NS; Sun T; Zhuo C; D'Souza G; Lee SH; Lan NH; Chiang CH; Wilson D; Sun F; Iaconis J; Melnick D
    Lancet Infect Dis; 2015 Feb; 15(2):161-71. PubMed ID: 25539586
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia.
    File TM; Segreti J; Dunbar L; Player R; Kohler R; Williams RR; Kojak C; Rubin A
    Antimicrob Agents Chemother; 1997 Sep; 41(9):1965-72. PubMed ID: 9303395
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical profile of ceftobiprole, a novel beta-lactam antibiotic.
    Noel GJ
    Clin Microbiol Infect; 2007 Jun; 13 Suppl 2():25-9. PubMed ID: 17488373
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Real-World Experience of Ceftobiprole for Community- and Hospital-Acquired Pneumonia from a Stewardship Perspective.
    Corcione S; De Benedetto I; Carlin M; Pivetta EE; Scabini S; Grosso C; Shbaklo N; Porta M; Lupia E; De Rosa FG
    Microorganisms; 2024 Apr; 12(4):. PubMed ID: 38674669
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ceftobiprole: A novel, broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus.
    Dauner DG; Nelson RE; Taketa DC
    Am J Health Syst Pharm; 2010 Jun; 67(12):983-93. PubMed ID: 20516468
    [TBL] [Abstract][Full Text] [Related]  

  • 53. CEFTO-CURE study: CEFTObiprole Clinical Use in Real-lifE - a multi-centre experience in Italy.
    Gentile I; Buonomo AR; Corcione S; Paradiso L; Giacobbe DR; Bavaro DF; Tiseo G; Sordella F; Bartoletti M; Palmiero G; Vozza A; Vena A; Canta F; Moriello NS; Congera P; Karruli A; Tascini C; Viale P; Bono VD; Falcone M; Carbonara S; Mikulska MK; Bassetti M; Durante-Mangoni E; De Rosa FG; Maraolo AE
    Int J Antimicrob Agents; 2023 Jul; 62(1):106817. PubMed ID: 37061102
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A randomized study of sequential intravenous/oral moxifloxacin in comparison to sequential intravenous ceftriaxone/oral cefuroxime axetil in patients with hospital-acquired pneumonia.
    Höffken G; Barth J; Rubinstein E; Beckmann H;
    Infection; 2007 Dec; 35(6):414-20. PubMed ID: 18034211
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cefepime: a review of its use in the management of hospitalized patients with pneumonia.
    Chapman TM; Perry CM
    Am J Respir Med; 2003; 2(1):75-107. PubMed ID: 14720024
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Model-Based Approach for Optimizing Ceftobiprole Dosage in Pediatric Patients.
    Rubino CM; Cammarata AP; Smits A; Schröpf S; Polak M; Litherland K; Hamed K
    Antimicrob Agents Chemother; 2021 Oct; 65(11):e0120621. PubMed ID: 34398669
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cefepime versus ceftazidime for treatment of pneumonia.
    Konstantinou K; Baddam K; Lanka A; Reddy K; Zervos M
    J Int Med Res; 2004; 32(1):84-93. PubMed ID: 14997712
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Real-life experience with ceftobiprole in Canada: Results from the CLEAR (CanadianLEadership onAntimicrobialReal-life usage) registry.
    Zhanel GG; Kosar J; Baxter M; Dhami R; Borgia S; Irfan N; MacDonald KS; Dow G; Lagacé-Wiens P; Dube M; Bergevin M; Tascini C; Keynan Y; Walkty A; Karlowsky J
    J Glob Antimicrob Resist; 2021 Mar; 24():335-339. PubMed ID: 33540083
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia.
    File TM; Low DE; Eckburg PB; Talbot GH; Friedland HD; Lee J; Llorens L; Critchley I; Thye D
    Clin Infect Dis; 2010 Dec; 51(12):1395-405. PubMed ID: 21067350
    [TBL] [Abstract][Full Text] [Related]  

  • 60. In vivo synergism of ceftobiprole and vancomycin against experimental endocarditis due to vancomycin-intermediate Staphylococcus aureus.
    Entenza JM; Veloso TR; Vouillamoz J; Giddey M; Majcherczyk P; Moreillon P
    Antimicrob Agents Chemother; 2011 Sep; 55(9):3977-84. PubMed ID: 21730114
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.